Misfolded PrP and a novel mechanism of proteasome inhibition

Prion

Volumn 6, Issue 1, 2012, Pages 32-36

  Andre, Ralph ^a   Tabrizi, Sarah J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Prion; Proteasome; Protein misfolding; Proteolysis; Proteostasis; PrP; UPS

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DNA 26S; PRION PROTEIN; PROTEASOME INHIBITOR; UBIQUITIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BETA SHEET; GENE EXPRESSION; HUNTINGTON CHOREA; IC 50; LEWY BODY; NEUROPIL; NOTE; PARKINSON DISEASE; PRION DISEASE; PROTEIN HOMEOSTASIS; PROTEIN HYDROLYSIS;

ANIMALS; HUMANS; MODELS, MOLECULAR; PRION DISEASES; PRIONS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; UBIQUITIN;

EID: 84857213897     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.6.1.18272     Document Type: Note

References (28)

1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216:136-44; PMID:6801762; http://dx.doi.org/10.1126/science. 6801762.
2. Büeler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993; 73:1339-47; PMID:8100741; http://dx.doi.org/10.1016/0092-8674(93)90360-3.
3. Mallucci GR, Ratte S, Asante EA, Linehan J, Gowland I, Jefferys JG, et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J 2002; 21:202-10; PMID:11823413; http://dx.doi.org/10.1093/emboj/21.3.202.
4. Goold R, Rabbanian S, Sutton L, Andre R, Arora P, Moonga J, et al. Rapid cell-surface prion protein conversion revealed using a novel cell system. Nat Commun 2011; 2:281; PMID:21505437; http://dx.doi.org/10.1038/ncomms1282.
5. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82:373-428; PMID:11917093.
6. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006; 443:780-6; PMID:17051204; http://dx.doi.org/10.1038/nature05291.
7. Bedford L, Hay D, Devoy A, Paine S, Powe DG, Seth R, et al. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 2008; 28:8189-98; PMID:18701681; http://dx.doi.org/10.1523/JNEUROSCI.2218-08.2008.
8. Kang SC, Brown DR, Whiteman M, Li R, Pan T, Perry G, et al. Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. J Pathol 2004; 203:603-8; PMID:15095484; http://dx.doi.org/10.1002/path.1555.
9. Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, Naumann H, et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell 2007; 26:175-88; PMID:17466621; http://dx.doi.org/10.1016/j.molcel. 2007.04.001.
10. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, et al. A gated channel into the proteasome core particle. Nat Struct Biol 2000; 7:1062-7; PMID:11062564; http://dx.doi.org/10.1038/80992.
11. Deriziotis P, Andre R, Smith DM, Goold R, Kinghorn KJ, Kristiansen M, et al. Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry. EMBO J 2011; 30:3065-77; PMID:21743439; http://dx.doi.org/10.1038/emboj.2011.224.
12. Smith DM, Chang SC, Park S, Finley D, Cheng Y, Goldberg AL. Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry. Mol Cell 2007; 27:731-44; PMID:17803938; http://dx.doi.org/10.1016/j.molcel.2007.06.033.
13. Whitby FG, Masters EI, Kramer L, Knowlton JR, Yao Y, Wang CC, et al. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 2000; 408:115-20; PMID:11081519; http://dx.doi.org/10.1038/35040607.
14. Förster A, Masters EI, Whitby FG, Robinson H, Hill CP. The 1.9 Å structure of a proteasome-11S activator complex and implications for proteasome-PAN/PA700 interactions. Mol Cell 2005; 18:589-99; PMID:15916965; http://dx.doi.org/10.1016/j.molcel.2005.04.016.
15. Yu Y, Smith DM, Kim HM, Rodriguez V, Goldberg AL, Cheng Y. Interactions of PAN's C-termini with archaeal 20S proteasome and implications for the eukaryotic proteasome-ATPase interactions. EMBO J 2010; 29:692-702; PMID:20019667; http://dx.doi.org/10.1038/emboj.2009.382.
16. Martins SM, Frosoni DJ, Martinez AM, De Felice FG, Ferreira ST. Formation of soluble oligomers and amyloid fibrils with physical properties of the scrapie isoform of the prion protein from the C-terminal domain of recombinant murine prion protein mPrP-(121-231). J Biol Chem 2006; 281:26121-8; PMID:16844683; http://dx.doi.org/10.1074/jbc.M605367200.
17. Gerber R, Tahiri-Alaoui A, Hore PJ, James W. Oligomerization of the human prion protein proceeds via a molten globule intermediate. J Biol Chem 2007; 282:6300-7; PMID:17210575; http://dx.doi.org/10.1074/jbc.M608926200.
18. Quaglio E, Restelli E, Garofoli A, Dossena S, De Luigi A, Tagliavacca L, et al. Expression of mutant or cytosolic PrP in transgenic mice and cells is not associated with endoplasmic reticulum stress or proteasome dysfunction. PLoS ONE 2011; 6:19339; PMID:21559407; http://dx.doi.org/10.1371/journal.pone. 0019339.
19. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 2000; 75:436-9; PMID:10854289; http://dx.doi.org/10.1046/j.1471-4159.2000.0750436.x.
20. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 2008; 29:1607-18; PMID:17544172; http://dx.doi.org/10.1016/j.neurobiolaging.2007.04. 014.
21. Gregori L, Fuchs C, Figueiredo-Pereira ME, Van Nostrand WE, Goldgaber D. Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem 1995; 270:19702-8; PMID:7649980; http://dx.doi.org/10.1074/jbc.270. 34.19702.
22. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001; 292:1552-5; PMID:11375494; http://dx.doi.org/10.1126/science.292.5521.1552.
23. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007; 448:704-8; PMID:17687326; http://dx.doi.org/10.1038/nature06022.
24. Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates GP. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. Hum Mol Genet 2006; 15:33-44; PMID:16311253; http://dx.doi.org/10.1093/ hmg/ddi423.
25. Bowman AB, Yoo SY, Dantuma NP, Zoghbi HY. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet 2005; 14:679-91; PMID:15661755; http://dx.doi.org/10. 1093/hmg/ddi064.
26. Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 2004; 279:12924-34; PMID:14711827; http://dx.doi.org/10.1074/jbc.M306390200.
27. Emmanouilidou E, Stefanis L, Vekrellis K. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol Aging 2010; 31:953-68; PMID:18715677; http://dx.doi.org/10.1016/j.neurobiolaging.2008.07. 008.
28. Lee BH, Lee MJ, Park S, Oh DC, Elsasser S, Chen PC, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010; 467:179-84; PMID:20829789; http://dx.doi.org/10.1038/nature09299.